Journal article

Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer

DJ Zanker, KL Owen, N Baschuk, AJ Spurling, BS Parker

Cancer Immunology Immunotherapy | SPRINGER | Published : 2021

Abstract

Competent type I IFN signaling is the lynchpin of most immune surveillance mechanisms and has recently proven critical to the efficacy of several anticancer agents. Expression of the type I IFN receptor, IFNAR, underpins type I IFN responsiveness in all cells and facilitates the activation and cytotoxic potential of lymphocytes, while loss of IFNAR on lymphocytes has previously been associated with tumor progression and poor patient survival. This study underscores the importance of intact type I IFN signaling to NK cells in the regulation of tumorigenesis and metastasis, whereby ablation of NK cell IFNAR1 impairs antitumor activity and tumor clearance. Using a preclinical model of triple ne..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Victorian Cancer Agency


Funding Acknowledgements

We thank the LARTF and Peter MacCallum Cancer Centre animal facility staff for assistance monitoring experimental animals. We thank Dr. Paul Beavis for the gifting of the B16F10 cell line. We thank Prof Christian Engwerda and Dr Fiona Amante at the QIMR Berghofer for the gifting of C57BL/6 Ifnar<SUP>fl/fl</SUP> and NKp46<SUP>iCre</SUP> mice. We acknowledge fellowship support from the Victorian Cancer Agency (BSP) and grant funding from the Cancer Council Victoria (BSP) for this work.